Sinotherapeutics Inc. A (688247) - Total Assets
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) holds total assets worth CN¥1.44 Billion CNY (≈ $211.22 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688247 net asset value for net asset value and shareholders' equity analysis.
Sinotherapeutics Inc. A - Total Assets Trend (2020–2024)
This chart illustrates how Sinotherapeutics Inc. A's total assets have evolved over time, based on quarterly financial data.
Sinotherapeutics Inc. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinotherapeutics Inc. A's total assets of CN¥1.44 Billion consist of 67.2% current assets and 32.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.5% |
| Accounts Receivable | CN¥103.52 Million | 7.1% |
| Inventory | CN¥102.42 Million | 7.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥21.65 Million | 1.5% |
| Goodwill | CN¥18.39 Million | 1.3% |
Asset Composition Trend (2020–2024)
This chart illustrates how Sinotherapeutics Inc. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sinotherapeutics Inc. A market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinotherapeutics Inc. A's current assets represent 67.2% of total assets in 2024, a decrease from 73.5% in 2020.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2024, down from 58.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 6.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 7.1% of total assets.
Sinotherapeutics Inc. A Competitors by Total Assets
Key competitors of Sinotherapeutics Inc. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Sinotherapeutics Inc. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.28 | 11.70 | 11.70 |
| Quick Ratio | 11.88 | 10.69 | 11.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥885.87 Million | CN¥864.31 Million | CN¥869.63 Million |
Sinotherapeutics Inc. A - Advanced Valuation Insights
This section examines the relationship between Sinotherapeutics Inc. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.38 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 6.7% |
| Total Assets | CN¥1.45 Billion |
| Market Capitalization | $636.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinotherapeutics Inc. A's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sinotherapeutics Inc. A's assets grew by 6.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sinotherapeutics Inc. A (2020–2024)
The table below shows the annual total assets of Sinotherapeutics Inc. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.45 Billion ≈ $212.66 Million |
+6.73% |
| 2023-12-31 | CN¥1.36 Billion ≈ $199.25 Million |
+2.20% |
| 2022-12-31 | CN¥1.33 Billion ≈ $194.96 Million |
+53.88% |
| 2021-12-31 | CN¥865.81 Million ≈ $126.69 Million |
+16.51% |
| 2020-12-31 | CN¥743.14 Million ≈ $108.74 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more